Avalo Therapeutics, focused on developing IL-1β-targeting biologics for immune-mediated inflammatory diseases, currently centers its growth hopes on the Phase 2 LOTUS trial of abdakibart in hidradenitis suppurativa. Despite completing enrollment in 2025 and expecting topline results in Q2 2026, the company has yet to generate meaningful revenue and reports mounting losses, with operating income deteriorating to -$72.9 million in 2025 [F1]. While it holds an exclusive patent portfolio and market rights extending potentially to 2045, Avalo's cash burn and clinical outcome dependence pose ongoing risks. The timeline for pivotal Phase 3 studies hinges on Phase 2 data readout with commercialization prospects sensitive to payor reimbursement dynamics and regulatory scrutiny [S1][S4][S17].